التداخل بين سيناكالسيت ونيرماتريلفير وريتونافير

Co-administration with a strong CYP3A4 inhibitor may increase serum levels of cinacalcet.

Dose adjustment of Sensipar may be required if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole).

Strong CYP3A4 Inhibitors Cinacalcet is partially metabolized by CYP3A4.

Potential for PAXLOVID to Affect Other Drugs PAXLOVID (nirmatrelvir co-packaged with ritonavir) is a strong inhibitor of CYP3A, and an inhibitor of CYP2D6, P-gp and OATP1B1.